- testing |
| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 5 Nov 2025 | 24 Oct 2025 |
| Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2025 ,inter alia, to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for quarter and half year ended 30th September, 2025. Please find enclosed outcome of Board Meeting held on November 5, 2025 Please find enclosed Unaudited Financial Results (Standalone & Consolidated) for quarter ended September 30, 2025 (As Per BSE Announcement Dated on 05.11.2025) | ||
| Board Meeting | 28 Jul 2025 | 18 Jul 2025 |
| Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2025 ,inter alia, to consider and approve Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2025 Please refer attachment Please refer attachment (As Per BSE Announcement Dated on :28.07.2025) | ||
| Board Meeting | 13 Jun 2025 | 13 Jun 2025 |
| Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (SEBI Listing Regulations) Appointment of N L Bhatia & Associates, Practicing Company Secretaries as Secretarial Auditors of the Company | ||
| Board Meeting | 14 May 2025 | 29 Apr 2025 |
| Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2025 inter alia to consider and approve the Audited Financial Results (Standalone and Consolidated) for the financial year ended 31st March 2025 and to consider recommending payment of dividend to the shareholders. Please refer attachment (As Per BSE Announcement dated on 14.05.2025) | ||
| Board Meeting | 28 Jan 2025 | 13 Jan 2025 |
| Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 inter alia to consider and approve Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 31st December 2024 Outcome of Board Meeting of Piramal Pharma Limited (Company) held on 28th January 2025. (As Per Bse Announcement Dated on 28.01.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.